US 11,806,409 B2
Imaging methods using 18F-radiolabeled biologics
David Donnelly, Doylestown, PA (US); and David K. Leung, West Windsor, NJ (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed on Nov. 10, 2022, as Appl. No. 17/984,825.
Application 17/984,825 is a continuation of application No. 17/196,274, filed on Mar. 9, 2021, granted, now 11,511,000.
Application 17/196,274 is a continuation of application No. 16/305,286, granted, now 10,994,033, issued on May 4, 2021, previously published as PCT/US2017/035271, filed on May 31, 2017.
Claims priority of provisional application 62/344,289, filed on Jun. 1, 2016.
Prior Publication US 2023/0241258 A1, Aug. 3, 2023
Int. Cl. A61K 51/08 (2006.01); A61K 49/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 51/088 (2013.01) [A61K 49/0004 (2013.01); C07K 16/2818 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method of monitoring the progress of an anti-tumor therapy against target-expressing tumors in a subject, the method comprising
(a) administering to the subject an imaging agent that binds specifically to the target molecule at a dose of about 3-10 mCi (100-333 MBq); and
(b) conducting a PET scan of the subject about 30-120 minutes after step (a), wherein steps (a) and (b) are conducted at least 1, 2, 3, 4 or 5 time points, one of which is prior to the initiation of the anti-tumor therapy, and at least one of which during the immunotherapy treatment, or wherein all time points are during the anti-tumor therapy, wherein the imaging agent comprises a protein linked to a radioactive PET tracer by a bifunctional conjugating moiety (BFC) comprising a reactive group that forms a covalent bond with an amine, carboxyl, carbonyl or thiol functional group on the protein, and
wherein the dimension and location of the diseased cells or tissue at each time point is indicative of the progress of the target-expressing tumor.